Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.57 +1.48 (+1.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,530,202
Open 90.92
Bid (Size) 91.16 (1)
Ask (Size) 93.30 (1)
Prev. Close 91.09
Today's Range 90.71 - 93.29
52wk Range 62.07 - 98.90
Shares Outstanding 1,253,809,440
Dividend Yield 3.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily

Performance

YTD
+11.21%
+11.21%
1 Month
+3.13%
+3.13%
3 Month
+10.22%
+10.22%
6 Month
+30.88%
+30.88%
1 Year
+16.21%
+16.21%

More News

Read More
COVID-19 is Not the Same Disease for Everyone
Via Brandpoint
Topics Death
Exposures COVID-19 Death
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
Is GILEAD SCIENCES INC Ready to Break Out of Its Range?
Via Chartmill
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
Looking At Gilead Sciences's Recent Unusual Options Activity
Via Benzinga
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
From Gilead Sciences, Inc.
Via Business Wire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
26 Analysts Assess Gilead Sciences: What You Need To Know
Via Benzinga
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Via Benzinga
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
From Gilead Sciences, Inc.
Via Business Wire
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
From Gilead Sciences, Inc.
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Via Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Via Benzinga
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
From Gilead Sciences, Inc.
Via Business Wire
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Via Benzinga
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.